On April 24, Kelun Pharmaceutical announced that Sichuan Kelun Pharmaceutical Co., Ltd. recently learned that the innovative drug KL210122 tablet developed by the company’s holding subsidiary Sichuan Kelun Botai Bio-Pharmaceutical Co., Ltd. has been approved by the National Drug Administration ) Notification of clinical trial.
The basic of drugs:
Drug name: KL210122 tablets
Dosage form: tablet
Specifications: 5mg; 20mg; 50mg; calculated as C24H29N6O4P.
Registration Classification: Registration Classification of Chemical Drugs 1
Applicant: Sichuan Kelun Botai Biomedical Co., Ltd.
Acceptance number: CXHL2100101, CXHL2100102, CXHL2100102
It is reported that KL210122 tablets are a new generation of tenofovir (TFV) prodrug with independent intellectual property rights independently developed by Kelun Pharmaceutical, with mature targets and a clear mechanism of action. Compared with TAF (tenofovir fumarate) or TDF (tenofovir disoproxil), it has obvious differentiating characteristics, and it is a promising third alternative with preclinical translational medicine evidence Nofovir.
As of February 2021, the company has invested approximately RMB 19.14 million in R&D expenses on the KL210122 film project.
Comments
Post a Comment